Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Reaffirmed by HC Wainwright
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $46.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 47.44% from the company’s previous close. […]
More Stories
What to Know About UAE Leaving OPEC
By Owen Evans The United Arab Emirates’ decision to leave the Organization of the Petroleum Exporting Countries (OPEC) next month...
FCC Orders Early Review of Disney’s ABC Station Licenses
By Jill McLaughlin The Federal Communications Commission (FCC) has ordered an early review of license renewals for Disney’s ABC television...
President Trump, First Lady Host King Charles, Queen Camilla for State Dinner
By Travis Gillmore WASHINGTON—First Lady Melania Trump organized a lavish state dinner co-hosted by her husband President Donald Trump in...
US Sanctions 35 Individuals, Entities to Dismantle Iran’s Shadow Banking
By Kimberly Hayek The U.S. Treasury Department on April 28 imposed sanctions on 35 individuals and entities accused of running...
Iran War Pushes Gulf Allies to Request Dollar Help—What to Know
By Andrew Moran Treasury Secretary Scott Bessent confirmed last week that several U.S. allies in the Gulf region and Asia...
DC Shooting Suspect Charged With Attempting to Assassinate Trump
By Stacy Robinson and Jackson Richman WASHINGTON—The Department of Justice has charged Cole Allen, the suspect in the White House...